Damora Therapeutics (DMRA) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 38.5% versus a loss of 24.6%. Over five years, DMRA leads with a -68.8% price change compared with -83.3% for SRPT. Damora Therapeutics is the larger company by market cap ($1.44 billion vs $1.43 billion), about 1.0 times the size.
On valuation, Damora Therapeutics trades at a lower trailing P/E (13.6x vs 666.5x for Sarepta Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | SRPT |
|---|---|---|
| Share price | $23.22 | $13.33 |
| Market cap | $1.44B | $1.43B |
| 1-day change | -4.44% | -5.93% |
| YTD return | +0.91% | -38.06% |
| 1-year return | +38.46% | -24.65% |
| 5-year return | -68.83% | -83.26% |
| P/E ratio (TTM) | 13.58 | 666.50 |
| Forward P/E | — | 8.87 |
| EPS (TTM) | $1.71 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.20B |
| Revenue growth (YoY) | — | +15.58% |
| Net income (latest FY) | $-209.84M | $-713.41M |
| Gross margin | — | 98.84% |
| Operating margin | — | -31.83% |
| Net margin | — | -32.45% |
| 52-week high | $38.33 | $24.68 |
| 52-week low | $15.76 | $13.25 |
| Distance from 52-week high | -39.41% | -45.99% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +101.46% | +63.32% |
| Average volume | 584.28K | 2.70M |
| Shares outstanding | 61.90M | 107.24M |
| Employees | 7 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed SRPT by 63.1 percentage points over the past year.
- Sarepta Therapeutics trades at a higher earnings multiple (666.5x vs 13.6x trailing P/E).
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
DMRA vs SRPT FAQ
Which is bigger, Damora Therapeutics or Sarepta Therapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.44B compared with $1.43B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, DMRA or SRPT?
DMRA returned +38.46% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DMRA or SRPT?
DMRA has the lower trailing P/E at 13.6, versus 666.5 for SRPT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Damora Therapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.